IL158003A0 - Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer - Google Patents

Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer

Info

Publication number
IL158003A0
IL158003A0 IL15800302A IL15800302A IL158003A0 IL 158003 A0 IL158003 A0 IL 158003A0 IL 15800302 A IL15800302 A IL 15800302A IL 15800302 A IL15800302 A IL 15800302A IL 158003 A0 IL158003 A0 IL 158003A0
Authority
IL
Israel
Prior art keywords
cancer
correlating
kits
evaluating
effectiveness
Prior art date
Application number
IL15800302A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/815,015 external-priority patent/US20030003454A1/en
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IL158003A0 publication Critical patent/IL158003A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15800302A 2001-03-23 2002-03-21 Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer IL158003A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/815,015 US20030003454A1 (en) 2001-03-23 2001-03-23 Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
US30333801P 2001-07-09 2001-07-09
PCT/IL2002/000231 WO2002076280A2 (fr) 2001-03-23 2002-03-21 Methodes et trousses servant a determiner le risque de developper un cancer, a evaluer l'efficacite et la posologie d'une therapie anticancereuse, et a etablir la correlation existant entre l'activite d'une enzyme de reparation de l'adn et un cancer

Publications (1)

Publication Number Publication Date
IL158003A0 true IL158003A0 (en) 2004-03-28

Family

ID=26973412

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15800302A IL158003A0 (en) 2001-03-23 2002-03-21 Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer

Country Status (7)

Country Link
US (2) US8043807B2 (fr)
EP (1) EP1430145B1 (fr)
JP (1) JP2005518779A (fr)
AU (1) AU2002241230B2 (fr)
CA (1) CA2441436C (fr)
IL (1) IL158003A0 (fr)
WO (1) WO2002076280A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123955A2 (fr) * 2004-06-09 2005-12-29 Children's Medical Center Corporation Procedes et compositions de modification de la regulation du gene et du dommage a l'adn en raison du vieillissement
WO2006126618A1 (fr) * 2005-05-26 2006-11-30 Signpost Corporation Procédé de détermination de polymorphisme de gène pour évaluer le niveau de risque de maladie, procédé d’évaluation du niveau de risque de maladie et matrice d'évaluation correspondante
CA2681577A1 (fr) * 2007-03-23 2008-10-02 F. Hoffmann-La Roche Ag Apex comme marqueur pour le cancer du poumon
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
EP2753716B1 (fr) * 2011-09-08 2017-11-01 Yeda Research and Development Co. Ltd. Nouveaux biomarqueurs de risque pour le cancer du poumon
US9637798B2 (en) * 2013-05-21 2017-05-02 Dignity Health Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
WO2015049371A1 (fr) * 2013-10-03 2015-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés permettant de prédire la faculté d'un patient atteint de leucémie myéloïde chronique (lmc) à répondre à un traitement comprenant un inhibiteur de tyrosine kinases (itk)
CA2982169A1 (fr) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Panels de biomarqueurs proteiques pour detecter le cancer colorectal et l'adenome avance
EP4014046A1 (fr) 2019-08-12 2022-06-22 Yeda Research and Development Co. Ltd Test sanguin de réparation de l'adn pour prédire la réponse de patients atteints d'un cancer du poumon à une immunothérapie
WO2023192499A1 (fr) * 2022-03-30 2023-10-05 Primefour Therapeutics, Inc. Nucléosides pour le traitement du cancer
WO2023192505A2 (fr) * 2022-03-30 2023-10-05 Primefour Therapeutics, Inc. Procédé de traitement du cancer avec un inhibiteur d'enzyme de réparation de dommages à l'adn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750093T2 (de) * 1986-01-17 1995-01-26 Daniel G Miller Test zur Feststellung der Empfänglichkeit für DNS-assoziierte Krankheiten.
US5482837A (en) 1994-01-14 1996-01-09 University Of Vermont Methods of identifying lymphocytes with mutator phenotypes
US7304662B1 (en) 1996-07-10 2007-12-04 Visilinx Inc. Video surveillance system and method
AU744157B2 (en) * 1997-07-28 2002-02-14 Fox Chase Cancer Center Novel gene encoding a DNA repair endonuclease and methods of use thereof
US20010031739A1 (en) 1999-12-21 2001-10-18 Dare Akintade Oyedele Method and kit for quantitating genomic DNA damage and repair capicity
US20030003454A1 (en) 2001-03-23 2003-01-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
JPWO2002077280A1 (ja) 2001-03-26 2004-10-14 齋藤　隆 シグナル伝達因子をコードする核酸のスクリーニング方法およびその方法に用いるキット並びに細胞

Also Published As

Publication number Publication date
EP1430145A2 (fr) 2004-06-23
US20040096863A1 (en) 2004-05-20
WO2002076280A2 (fr) 2002-10-03
CA2441436A1 (fr) 2002-10-03
JP2005518779A (ja) 2005-06-30
EP1430145B1 (fr) 2013-01-02
CA2441436C (fr) 2011-06-07
AU2002241230B2 (en) 2007-11-29
US8043807B2 (en) 2011-10-25
EP1430145A4 (fr) 2006-08-16
WO2002076280A3 (fr) 2004-03-18
US20110294134A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO1999067417A3 (fr) Analyse de potentiel biochimique et methodes associees
EP1879496A4 (fr) Dispositif, systeme et procede permettant de determiner l'effet de la therapie tumorale photodynamique ou photothermique
GB0418542D0 (en) Integrated biosensor and simulation system for diagnosis and therapy
IL158003A0 (en) Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer
EP1575574A4 (fr) Methodes de traitement et de prevention de maladies relatives a l'apoptose mettant en oeuvre des agents interferant avec l'arn
EP1482916A4 (fr) Therapie a base des cellules de schwann et des inhibiteurs de phosphodiesterase
EP1774043A4 (fr) Compositions, kits et procedes pour identifier, evaluer, prevenir et traiter un cancer
EP1547611A4 (fr) Medicament et procede de traitement des maladies de la prostate
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
MXPA03008691A (es) Metodo para tratamiento de enfermedades proliperativas usando inhibidores eg5.
AU2003263611A8 (en) Method for diagnosing prostate cancer
WO2004033666A3 (fr) Procedes et composes pour inhiber l'activite de hec1 dans le traitement des maladies proliferatives
IS5742A (is) Aðferð til genalækninga
EP1668337A4 (fr) Methodes d'optimisation de la reactivite clinique a une therapie au methotrexate au moyen d'un profilage de metabolite et de la pharmacogenetique
WO2002090925A3 (fr) Polypeptides acides nucleiques associes au cancer
WO2003073818A3 (fr) Analyse du proteome de tumeurs pour developpement de rapport consultatif d'options therapeutiques
MXPA05006034A (es) Proteina de duplicacion.
EP1268860A4 (fr) Stratification de patients a des fins de therapie du cancer sur la base de l'analyse de micro-reseaux d'adn genomique
IL158003A (en) Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer
FI20021565A0 (fi) Menetelmä ja järjestelmä teräksen karkaisusyvyyden määrittämiseksi
EP1506401A4 (fr) Procede d'analyse de formes proenzymatiques d'antigenes specifiques de la prostate dans des serums pour ameliorer la detection du cancer de la prostate
AU2003250912A8 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
AU2003288914A8 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP1539957A4 (fr) Nouvelles methodes de diagnostic et de therapie et reactifs correspondants